This week’s FDA COVID-19 updates

By Jenni Spinner contact

- Last updated on GMT

(bennymarty/iStock via Getty Images Plus)
(bennymarty/iStock via Getty Images Plus)

Related tags: Fda, Diagnostics, COVID-19, Coronavirus

The US agency continues releasing resources, offering advice and taking actions related to the pandemic, and how life-sciences professionals respond.

To date, there have been 15.3m confirmed COVID-19 cases around the world, with about 4m in the US alone. In response to the pandemic, the US Food and Drug Administration (FDA) continues to issue advice, hand out emergency use authorizations, release guidance documents, and react to fraudulent products.

EUA to Quest

The agency this week reissued an emergency use authorization (EUA) to national testing company Quest Diagnostics for its Quest SARS-CoV-2 rRT-PCR test. It is now authorized for use with pooled samples containing up to four individual upper-respiratory swab specimens collected under observation.

According to the agency, the Quest Diagnostic test is the first COVID-19 diagnostic test to be authorized for use with pooled samples.

Hotline goes cold

On Friday July 17, the FDA shot down its COVID-19 Industry Hotline. The phone line was created to serve as a resource for life-sciences, pharmaceutical and medical professionals to obtain answers to various questions.

As an alternative, the agency will provide support for developers, researchers, laboratories and other professionals online. The information can be found through the Contacts for Medical Devices During the COVID-19 Pandemic​ directory.

Testing information

The agency updated its Frequently Asked Questions on Testing for SARS-CoV-2​. The revised FAQs resource include a list of laboratories that have been removed from the list of laboratories that had notified FDA that they had developed and validated diagnostic tests as set forth in Section IV.A of the Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)​.

According to the FDA, the laboratories taken off the list were removed because the agency determined there are significant problems with the associated tests that cannot be, or have not been, addressed in a timely manner and should no longer be used.

Guiding against fraud

In a recently issued document in the FDA Voices series, titled FDA Protects Patients and Consumers from Fraud During COVID-19​, FDA representatives explain the agency’s work to prevent fraudulent preventive or curative products from reaching consumers’ hands. To date, the FDA has not approved any such products to treat the virus.

Related news

Show more

Related products

show more

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Related suppliers

Follow us


View more